Jatinder K Lamba
Overview
Explore the profile of Jatinder K Lamba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paragji A, Shastri V, Nasri E, Ligon J, Elliott L, Castillo-Caro P, et al.
Mol Oncol
. 2025 Mar;
PMID: 40080912
Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however,...
2.
Nguyen N, Nguyen N, Rafiee R, Parcha P, Parcha P, Tagmount A, et al.
Blood Adv
. 2024 Dec;
9(5):1078-1091.
PMID: 39715471
Cytarabine, daunorubicin, and etoposide (ADE) have been the standard backbone of induction chemotherapy regimen for patients with pediatric acute myeloid leukemia (pAML) for >5 decades. However, chemoresistance is still a...
3.
Seffernick A, Cao X, Cheng C, Yang W, Autry R, Yang J, et al.
bioRxiv
. 2024 Aug;
PMID: 39131398
Motivation: Large datasets containing multiple clinical and omics measurements for each subject motivate the development of new statistical methods to integrate these data to advance scientific discovery. Model: We propose...
4.
H Elsayed A, Cao X, Marrero R, Nguyen N, Wu H, Ni Y, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):168.
PMID: 39090192
In this study, we leveraged machine-learning tools by evaluating expression of genes of pharmacological relevance to standard-AML chemotherapy (ara-C/daunorubicin/etoposide) in a discovery-cohort of pediatric AML patients (N = 163; NCT00136084...
5.
Marrero R, Wu H, Cao X, Parcha P, H Elsayed A, Inaba H, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4388-4396.
PMID: 39078289
Purpose: Cytarabine (also known as ara-C) has been the backbone of acute myeloid leukemia (AML) chemotherapy for more than five decades. Recent pharmacogenomics-based 10-SNP ara-C (ACS10) scores showed low ACS10...
6.
Lamba J, Marrero R, Wu H, Cao X, Parcha P, Karol S, et al.
JAMA Netw Open
. 2024 May;
7(5):e2411726.
PMID: 38753328
Importance: Disparities in outcomes exist between Black and White patients with acute myeloid leukemia (AML), with Black patients experiencing poorer prognosis compared with their White counterparts. Objective: To assess whether...
7.
Shastri V, Chauhan L, Gbadamosi M, Alonzo T, Wang Y, Aplenc R, et al.
Clin Cancer Res
. 2024 Jan;
31(5):890-898.
PMID: 38197878
Purpose: Comprehensive pharmacogenomics (PGx) evaluation of calicheamicin pathway to identify predictive PGx markers of response to gemtuzumab ozogamicin (GO) treatment in acute myeloid leukemia (AML). Experimental Design: SNPs in DNA...
8.
Seligson N, Kolesar J, Alam B, Baker L, Lamba J, Fridley B, et al.
Pharmacogenomics
. 2023 Sep;
24(13):731-738.
PMID: 37702060
Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy...
9.
Marrero R, Lamba J
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509244
Acute myeloid leukemia (AML) is a clonal hematopoietic disease that arises from chromosomal and genetic aberrations in myeloid precursor cells. AML is one of the most common types of acute...
10.
Larkin T, Kashif R, H Elsayed A, Greer B, Mangrola K, Rafiee R, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200580.
PMID: 36952646
Purpose: Acute lymphoblastic leukemia (ALL) is the most prevalent cause of childhood cancer and requires a long course of therapy consisting of three primary phases with interval intensification blocks. Although...